Xtalks — The Life Science Community™, Online webinar
2026-12-15
Decisions made early in the drug development process from preclinical through Phase IIa can disproportionately impact later development as costs increase with each phase. Timely information quantifying drug distribution to tissues of interest, the relationship between plasma concentration and target occupancy and pharmacodynamic effects of drugs engaging the target can significantly reduce the costs, complexity and failure rate of later-stage clinical trials. This webinar explores how PET and MRI imaging methods can provide biologically meaningful outcome measures that support earlier drug development decisions. Early evaluation of potential imaging biomarkers and their integration into the development pipeline can provide substantial benefits to a portfolio of compounds under development. The featured speaker will discuss the role of different imaging methods used to evaluate biologically meaningful outcome measures across the drug development pipeline, including the time and resource requirements needed to integrate these methods effectively into development programs. This webinar will focus on CNS drug development as one of the more established therapeutic areas to employ imaging methods, while applying principles that are applicable across the therapeutic spectrum. Register for this webinar to learn how imaging methods can support confident go/no-go decision-making and optimize drug development planning.
|